LOS ANGELES, Feb. 23, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced the appointment of L. Stephen Coles, M.D., Ph.D. to the Company's Board of Directors. Dr. Coles has more than four decades experience in healthcare practice and technology management in both government and the private sector.
"Stephen Coles brings exceptional medical, scientific and business experience to the Board of Genesis Biopharma," said Anthony J. Cataldo, President and Chief Executive Officer. "In addition to being a recognized authority in medical technology and biostatistics, he is also a successful entrepreneur and innovator, having founded two high technology companies. His background and expertise will play an important role in the Company's growth."
Dr. Coles is currently a Lecturer in the Department of Chemistry and Biochemistry at the University of California Los Angeles, and at the UCLA Molecular Biology Institute. Previously he served as Co-Principal Investigator in the Department of Surgery at the UCLA School of Medicine, and as Vice President for Medical Education and Internet Content at The Kronos Group. He is also the co-founder of Image Data Corporation, where he served as Chief Scientist, and Rcommunity.com, Inc., where he was Chief Technical Officer.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the company, visit www.genesis-biopharma.com.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "ma
|SOURCE Genesis Biopharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved